Apyx Medical Reaffirms 2026 Revenue Guidance Amid 9% Year-over-Year Growth
Apyx Medical (APYX) reported third-quarter revenue of $14 million, representing a 9% increase compared to the same period in 2025. CEO Charles Goodwin attributed this growth to strong year-over-year performance across the company's operations. Looking ahead, the company reaffirmed its full-year 2026 revenue guidance of $59 million to $60 million. Notably, management has tightened its operating expense target to a range of $41 million to $42.5 million, signaling an increased focus on cost discipline and margin management.
Tickers: $APYX
Topics: management commentary quarterly earnings revenue growth